The neoadjuvant combination of camrelizumab, nab-paclitaxel & cisplatin demonstrated statistically significant enhancements in pCRs compared with solitary chemotherapy in resectable locally advanced esophageal squamous cell carcinoma. https://lnkd.in/ei3axH2q
Targeted Oncology’s Post
More Relevant Posts
-
Cohort study aims to establish whether anterior vs posterior tumor extension may represent a prognostic factor in oral tongue and floor squamous cell carcinoma. https://ja.ma/3ODk2Q9
To view or add a comment, sign in
-
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
To view or add a comment, sign in
-
Gain valuable insights into how collaboration among different healthcare professionals can lead to early detection and better outcomes for patients with advanced cases of basal cell carcinoma (BCC) and advanced cutaneous squamous cell carcinoma (CSCC). Register here: https://okt.to/jbM5hq
To view or add a comment, sign in
-
Gain valuable insights into how collaboration among different healthcare professionals can lead to early detection and better outcomes for patients with advanced cases of basal cell carcinoma (BCC) and advanced cutaneous squamous cell carcinoma (CSCC). Register here: https://okt.to/RpId8e
To view or add a comment, sign in
-
Transitional Cell Carcinoma Illustration showing the enhancement of transitional cell carcinoma across the 4 phases of CT. https://lnkd.in/eui6ynYx
To view or add a comment, sign in
-
Summary: The article discusses the promising efficacy of a chemotherapy-free regimen combining eftilagimod alpha with pembrolizumab in patients with advanced PD-L1-negative head and neck squamous cell carcinoma
web link
assets.medpagetoday.net
To view or add a comment, sign in
-
The #KIT ligand #KITLG promotes portal vein tumor #thrombosis by up-regulating COL4A1 through STAT3-SMAD2 signaling in hepatocellular carcinoma https://lnkd.in/egPH4d6Y
To view or add a comment, sign in
-
𝙀𝙛𝙛𝙞𝙘𝙖𝙘𝙮 𝙖𝙣𝙙 𝙩𝙤𝙭𝙞𝙘𝙞𝙩𝙮 𝙤𝙛 𝙖𝙣𝙡𝙤𝙩𝙞𝙣𝙞𝙗 𝙥𝙡𝙪𝙨 𝙘𝙖𝙢𝙧𝙚𝙡𝙞𝙯𝙪𝙢𝙖𝙗 𝙫𝙚𝙧𝙨𝙪𝙨 𝙖𝙣𝙡𝙤𝙩𝙞𝙣𝙞𝙗 𝙥𝙡𝙪𝙨 𝙎-1 𝙖𝙨 𝙨𝙚𝙘𝙤𝙣𝙙-𝙡𝙞𝙣𝙚 𝙩𝙝𝙚𝙧𝙖𝙥𝙮 𝙛𝙤𝙧 𝙖𝙙𝙫𝙖𝙣𝙘𝙚𝙙 𝙚𝙨𝙤𝙥𝙝𝙖𝙜𝙚𝙖𝙡 𝙨𝙦𝙪𝙖𝙢𝙤𝙪𝙨 𝙘𝙚𝙡𝙡 𝙘𝙖𝙧𝙘𝙞𝙣𝙤𝙢𝙖: 𝘼 𝙧𝙚𝙖𝙡-𝙬𝙤𝙧𝙡𝙙 𝙧𝙚𝙩𝙧𝙤𝙨𝙥𝙚𝙘𝙩𝙞𝙫𝙚 𝙨𝙩𝙪𝙙𝙮. A recent study explores #anlotinib plus #camrelizumab as a #secondlinetherapy for advanced #esophagealsquamouscell #carcinoma. Promising results show longer #survival time, improved #diseasecontrol, and manageable #sideeffects. Read more here: https://lnkd.in/gVBZT7KW
To view or add a comment, sign in
-
Chief of pathology and molecular pathology at Instituto Nacional De Cancerología / Scientific research at Fundación Universitaria de Ciencias de la Salud
We are glad to show our most recent article. PD-L1 expression in non-small cell lung carcinoma in Latin America: a systematic review and meta-analysis https://lnkd.in/eeR4bUxb
To view or add a comment, sign in
-
Clinical response of T3 squamous cell carcinoma of the tongue, treated with neoadjuvant pembrolizumab-carboplatin-paclitaxel. Significant reduction of the tumor size.
To view or add a comment, sign in
54,824 followers
More from this author
-
The Targeted Pulse: Discover the Latest From ODAC and Recent Treatment Updates in Myeloma, NSCLC, and Prostate Cancer
Targeted Oncology 3d -
The Targeted Pulse: NKT2152 Sparks Excitement in RCC, Amivantamab/Chemotherapy Combo Receives Approval for EGFR-Mutant NSCLC, and More
Targeted Oncology 1w -
The Targeted Pulse: Adagrasib Bests Docetaxel in Pretreated KRAS G12C-NSCLC, Adding Nivolumab to Tivozanib Yields No benefit in RCC, and More
Targeted Oncology 2w